Biogen's CEO says the company's late-stage pipeline is in good shape, but the drugmaker is still hunting for deals to build ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Here's a roundup of Boston-area ...

Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...

Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million in upfront cash for the rights to Vanqua Bio’s preclinical C5aR1 antagonist. Biogen described C5aR1 as a ...

CAMBRIDGE, Mass. — Biogen on Tuesday held a ceremonial groundbreaking of its 16-story headquarters in Kendall Square, ushering in the latest phase of the neighborhood’s transformation from “Nowhere ...

Biogen (NASDAQ:BIIB) said that it has agreed to acquire Alcyone Therapeutics, a company based in Massachusetts. The deal involves an upfront payment of $85M, along with additional milestone payments ...

As momentum for Biogen’s newer drugs for neurological disorders builds at a slow and steady pace, it appears that the company can still count on its older products to hold down the fort and support ...

Naomi Fried, Boston Children’s Hospital’s Chief Innovation Officer, is leaving the hospital to become Vice President of Medical Information, Innovation, and External Partnerships at Biogen Idec, ...

Biogen has given Alcyone Therapeutics a starring role in its drug delivery strategy, paying $85 million to buy the biotech and take control of an implant for getting medicines into the spinal canal.

Despite possessing a solid data package on the potential of high-dose Sprinraza in spinal muscular atrophy (SMA), Biogen will now need to revise its application if it hopes to secure an FDA nod. The ...

Biogen said it intends to invest an additional $2 billion over the next three years to expand operations at its largest manufacturing facilities within North Carolina’s Research Triangle Park (RTP).